Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) · 2025
[Successful subcutaneous desensitization in a patient with systemic reaction due to ixekizumab].
Клинический случайАннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gutiérrez-Fernández Diego, Saldaña-Valderas Mónica, Iriarte-Gahete Marianela, De la Varga-Martínez Raquel, Pamies-Espinosa Rafael, Roldán-Morales Jose Carlos, Franzón-Laz Zahira Maria, Doménech-W Joan
Аннотация
BACKGROUND: Ixekizumab is a high-affinity IgG4 monoclonal humanized antibody useful for the treatment of ankylosing spondylitis. Benign skin reactions are a common adverse event with ixekizumab but systemic hypersensitivity reactions are much more unusual.
CASE REPORT: We describe the case of a 54-female patient with HLAB27+ spondyloarthritis. Treatment with ixekizumab 80 mg subcutaneous (containing polysorbate) was prescribed. The patient experienced immediate severe dyspnea, skin erythema and flushing. Intradermal test (0.8 mg/ml) was clearly positive in the immediate reading. The patient was planned to undergo ixekizumab desensitization according to an 8-step protocol with good tolerance.
CONCLUSION: We report a patient with HLAB27+ spondyloarthritis treated with ixekizumab who developed a systemic IgE-mediated reaction. A successful and easy to perform subcutaneous desensitization protocol is described.
CASE REPORT: We describe the case of a 54-female patient with HLAB27+ spondyloarthritis. Treatment with ixekizumab 80 mg subcutaneous (containing polysorbate) was prescribed. The patient experienced immediate severe dyspnea, skin erythema and flushing. Intradermal test (0.8 mg/ml) was clearly positive in the immediate reading. The patient was planned to undergo ixekizumab desensitization according to an 8-step protocol with good tolerance.
CONCLUSION: We report a patient with HLAB27+ spondyloarthritis treated with ixekizumab who developed a systemic IgE-mediated reaction. A successful and easy to perform subcutaneous desensitization protocol is described.